Literature DB >> 16689921

Economic evaluation of measles catch-up and follow-up campaigns in Afghanistan in 2002 and 2003.

Maya Vijayaraghavan1, Fabio Lievano, Lisa Cairns, Lara Wolfson, Robin Nandy, Amir Ansari, Anne Golaz, Taufiq Mashal, Peter Salama.   

Abstract

This paper assesses the cost-effectiveness of, and the return on the investment in, the 2002 catch-up and the 2003 follow-up measles campaigns in Afghanistan from the perspective of the donor. The catch-up campaign targeted nearly 12 million children aged between six months and 12 years, while the follow-up campaign targeted over five million children aged between 9 and 59 months. Both campaigns successfully vaccinated approximately 96 per cent of the respective target populations, and are expected to avert an estimated 301,000 measles deaths over the next 10 years. The average cost per dose of measles vaccine delivered was USD 0.40. The cost per death prevented is USD 23.6, assuming a case fatality rate of 10 per cent and a discount rate of three per cent. With more than 42,000 measles deaths avoided for every one million US dollars spent, the campaigns are an excellent public health investment for precluding childhood mortality in a country affected by a complex emergency.

Entities:  

Mesh:

Year:  2006        PMID: 16689921     DOI: 10.1111/j.0361-3666.2006.00318.x

Source DB:  PubMed          Journal:  Disasters        ISSN: 0361-3666


  9 in total

1.  Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.

Authors:  Lara J Wolfson; François Gasse; Shook-Pui Lee-Martin; Patrick Lydon; Ahmed Magan; Abdelmajid Tibouti; Benjamin Johns; Raymond Hutubessy; Peter Salama; Jean-Marie Okwo-Bele
Journal:  Bull World Health Organ       Date:  2008-01       Impact factor: 9.408

2.  Measles vaccination in humanitarian emergencies: a review of recent practice.

Authors:  Rebecca F Grais; Peter Strebel; Peter Mala; John Watson; Robin Nandy; Michelle Gayer
Journal:  Confl Health       Date:  2011-09-26       Impact factor: 2.723

3.  Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.

Authors:  Gian Gandhi; Patrick Lydon
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

4.  Aid effectiveness in rebuilding the Afghan health system: a reflection.

Authors:  Suraya Dalil; William Newbrander; Benjamin Loevinsohn; Ahmad Jan Naeem; James Griffin; Peter Salama; Faiz Mohammad Momand
Journal:  Glob Public Health       Date:  2014-06-12

5.  Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world - Can elimination be maintained?

Authors:  J M Prada; C J E Metcalf; S Takahashi; J Lessler; A J Tatem; M Ferrari
Journal:  Vaccine       Date:  2017-02-16       Impact factor: 3.641

Review 6.  Does health economics research align with the disease burden in the Middle East and North Africa region? A systematic review of economic evaluation studies on public health interventions.

Authors:  Mouaddh Abdulmalik Nagi; Mustafa Ali Ali Rezq; Sermsiri Sangroongruangsri; Montarat Thavorncharoensap; Pramitha Esha Nirmala Dewi
Journal:  Glob Health Res Policy       Date:  2022-07-25

7.  Impact of conflict on infant immunisation coverage in Afghanistan: a countrywide study 2000-2003.

Authors:  Taufiq Mashal; Keiko Nakamura; Masashi Kizuki; Kaoruko Seino; Takehito Takano
Journal:  Int J Health Geogr       Date:  2007-06-07       Impact factor: 3.918

Review 8.  Global trends in measles publications.

Authors:  Rachel Kornbluh; Robert Davis
Journal:  Pan Afr Med J       Date:  2020-02-20

9.  Analysing the characteristics of a measles outbreak in Houaphanh province to guide measles elimination in the Lao People's Democratic Republic.

Authors:  Bounthanom Sengkeopraseuth; Bouaphanh Khamphaphongphane; Phengta Vongphrachanh; Anonh Xeuatvongsa; Sisouveth Norasingh; Chansay Pathammvong; Manilay Phengxay; Phanmanisone Philakong; Siddhartha Sankar Datta
Journal:  Western Pac Surveill Response J       Date:  2018-07-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.